Health Care · Surgical & Medical Instruments & Apparatus

PODD Insulet Corporation SEC Filings & Insider Trading Activity 2026

company
CIK 1145197110 filings
S&P 500

PODD at a glance

Insulet Corporation (PODD, SEC CIK 1145197) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Insulet Corporation (PODD) reported revenue of $2.7 billion (up 30.7% from FY2024) and net income of $247.1 million. Diluted EPS was $3.48.
  • As of June 30, 2025, 12 institutional investment managers tracked by SignalX reported holding Insulet Corporation (PODD) shares worth $155.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by McEvoy Ashley on August 21, 2026 of 1,100 shares at $147.47 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.7B
+30.7% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
12 funds
$155.2M · +3 vs prior quarter
Latest 8-K
Nov 20, 2026
Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue $2,708.1M in 2025, up 30.7% YoY (+$636.6M); U.S. revenue $1,919.8M (+27.2%), International $754.3M (+44.1%)
  • Gross margin 71.6% in 2025 vs 69.8% in 2024; R&D expense 11.1% of revenue vs 10.6%; SG&A 43.0% vs 44.3%
  • Best segment: International Omnipod Products up $230.9M (44.1%); worst: Drug Delivery down 12.3% or $4.8M to $34.1M
  • Free cash flow $377.7M, up $72.4M; Capex $191.6M (+53%), share repurchase $59.6M in 2025, $300M planned in Q1 2026
  • 2026 outlook: Expected strong U.S. and International revenue growth from recurring sales and Omnipod 5 adoption; tariff risk if medical device exemptions eliminated

Business Overview

  • Core business in marketing and product training within healthcare, focusing on compliance with complex healthcare laws like Medicare, Medicaid, and anti-bribery statutes
  • Emphasis on advanced AI tool deployment and adherence to evolving global privacy, data protection, and AI regulations including EU AI Act by August 2026
  • Strategic focus on managing cybersecurity risks and potential data breaches amid increased reliance on cloud-hosted systems and AI infrastructure
  • Notable leadership changes in 2025 including new CEO and CFO, impacting talent retention and operational continuity
  • Elevated regulatory and compliance risks due to expanded data privacy laws (e.g., CCPA, CPRA), complex IT security challenges, and credit agreement restrictions affecting capital flexibility

Risk Factors

  • Cybersecurity risk oversight primarily by NGR Committee with regular updates from CISO and strategic roadmap reviews
  • CISO reports to CTO, leading cybersecurity program including risk detection and continuous improvement in medical device manufacturing
  • CTO with 15+ years experience co-chairs Technology Risk Committee ensuring cybersecurity governance and remediation actions
  • No specific regulatory, geopolitical, operational, competitive, or financial risks detailed beyond cybersecurity governance

AI summary of the PODD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risks disclosed in the December 31, 2025 Form 10-K
  • Carried-forward risks include business, financial condition, results of operations, and cash flows exposures

Management Discussion & Analysis

  • Revenue $842.0M, up 19.2% YoY from $706.3M, driven by Omnipod Products growth
  • Gross margin 75.1% vs 72.2% YoY, benefiting from manufacturing efficiencies and warranty accrual adjustment
  • International Omnipod revenue $266.2M, up 31.7%; Drug Delivery $5.5M, down 22.7%
  • Operating cash flow $325.7M, down from $386.0M; capital expenditures $113.9M and share repurchases $300.0M
  • 2026 capital expenditures expected to increase; tariff exemption removal could materially pressure future gross margin

AI summary of the PODD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 20, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Michael R. Minogue reappointed as Class I director effective November 20, 2026, term through 2029 annual meeting
  • Return restores prior healthcare leadership and medtech expertise following September 2026 resignation
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results for the quarter ended September 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • $1 billion share repurchase authorization through December 31, 2028
  • Approximately $400 million targeted for fourth-quarter 2026 repurchases using existing cash

Item EX-99.1: Item EX-99.1

  • Q3 revenue $842.0M, up 19.2%, slightly above constant-currency guidance ceiling
  • Omnipod revenue $836.6M, up 19.7%, led by international growth of 31.7%
Filed Sep 21, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $475 million existing term loans refinanced at par, with 0.25% lower interest-rate margins
  • New term-loan margins: 0.75% base rate and 1.75% term SOFR, with 0.00% SOFR floor

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01, indicating a material financial obligation arises from the agreement described there
  • Investor impact depends on Item 1.01 terms, including obligation size, payment structure, maturity and related commitments

AI summaries of PODD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PODD

Don't miss the next PODD filing

  • Alerts as it files. A push when PODD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PODD, by share count.
  • Ask anything. An AI agent that reads every PODD filing and answers with sources.

PODD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Pease FlaviaFOct 1, 2026$130.79
MAZELSKY JONATHAN JAYASep 30, 2026$130.47
Huffines Robert LutherASep 30, 2026$130.47
McEvoy AshleyBuyAug 21, 2026$147.47
Davis Lisa BlairFAug 1, 2026$165.35
Davis Lisa BlairFAug 1, 2026$165.35
Huffines Robert LutherAJun 30, 2026$152.25
Huffines Robert LutherAJun 30, 2026$152.25

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.1B$2.7B
Gross Profit-$1.4B$1.9B
Operating Income-$308.9M$473.8M
Net Income-$418.3M$247.1M
Gross Margin-69.8%71.6%
Op. Margin-14.9%17.5%
Net Margin-20.2%9.1%
Balance Sheet
Total Assets$2.6B$3.1B$3.2B
Equity$732.7M$1.2B$1.5B
ROE-34.5%16.3%
Per Share
EPS-$5.78$3.48
Cash Flow
Operating CF-$430.3M$569.3M
CapEx-$124.9M$191.6M

Source: XBRL data in Insulet Corporation (PODD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2025

Aggregate PODD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PODD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202512$155.2M
Q1 20259$132.0M
Q4 20248$182.0M
Position changes: Q1 2025 → Q2 2025
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 29 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PODD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 20, 2026Analysis-
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 5, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
8-KSep 21, 2026Analysis-
8-KSep 16, 2026Analysis-
8-KSep 10, 2026Analysis-
4Aug 24, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Aug 4, 2026--
4Jul 7, 2026--
8-KJun 25, 2026Analysis-
4Jun 4, 2026-
4Jun 4, 2026-
8-KMay 26, 2026Analysis
8-KMay 21, 2026Analysis
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-

Related Health Care companies

All Health Care →

PODD SEC filings: frequently asked questions

Which institutions hold PODD stock?

As of June 30, 2025, the largest Insulet Corporation (PODD) holders among the 13F filers tracked by SignalX were Franklin Resources ($73.9 million), D.E. Shaw & Co ($26.8 million), Citigroup ($12.2 million), State Street Corp ($10.5 million), JPMorgan Chase & Co ($7.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PODD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Insulet Corporation (PODD) reported revenue of $2.7 billion (up 30.7% from FY2024) and net income of $247.1 million. Diluted EPS was $3.48. The figures come from the XBRL data in the 10-K.

What are the main risks in PODD's latest 10-K?

In the 10-K filed February 18, 2026, Insulet Corporation (PODD) flagged: Cybersecurity risk oversight primarily by NGR Committee with regular updates from CISO and strategic roadmap reviews. CISO reports to CTO, leading cybersecurity program including risk detection and continuous improvement in medical device manufacturing. (AI summary of the Risk Factors section.)

What did PODD report in its latest 8-K?

Insulet Corporation (PODD) filed an 8-K on November 20, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Michael R. Minogue reappointed as Class I director effective November 20, 2026, term through 2029 annual meeting.

What are the latest PODD SEC filings?

Insulet Corporation (PODD) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on October 5, 2026.

What is PODD's SEC CIK number?

Insulet Corporation (PODD)'s SEC Central Index Key (CIK) is 1145197. EDGAR lists every PODD filing under that number.

Ask anything about PODD

The research agent reads PODD's filings, financials, insider trades and 13F holders, then answers with sources.